Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the incidence of and strategies for monitoring depression during interferon-based HCV antiviral therapy
- Describe strategies for managing depression that emerges during HCV therapy
- Articulate how the shortening of treatment can be used in genotype 2/3 HCV–infected patients who develop depressive symptoms during therapy
- Recall the incidence and management strategies for the development of suicidal ideation during HCV therapy
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.